Anti-Cdk4 antibody (ab16516)

Overview

• Product nameAnti-Cdk4 antibodySee all Cdk4 primary antibodies ...
• Description
  Rabbit polyclonal to Cdk4
• Tested applicationsWB, IP more details
• Species reactivity
  Reacts with: Human
  
• Immunogen

  TrpE fusion protein containing C-terminal 164 amino acids of Cdk4 (Human).

• Positive controlHeLa cell lysate

Properties

• FormLiquid
• Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: 0.08% Sodium Azide
  Constituents: PBS
• Concentration information loading...
• PurityImmunogen affinity purified
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Cancer
  • Cell cycle
  • Kinases/phosphatases
  • Cdks

  • Epigenetics and Nuclear Signaling
  • Cell cycle
  • Kinases/Phosphatases
  • Cdks

  • Cell Biology
  • Cell Cycle
  • Kinases/Phosphatases
  • Cdks

Applications

Target

• FunctionSer/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
• Involvement in diseaseDefects in CDK4 are a cause of susceptibility to cutaneous malignant melanoma type 3 (CMM3) [MIM:609048]. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
• Sequence similaritiesBelongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.
  Contains 1 protein kinase domain.
• Post-translational
  modificationsPhosphorylation at Thr-172 is required for enzymatic activity. Phosphorylated, in vitro, at this site by CCNH-CDK7, but, in vivo, appears to be phosphorylated by a proline-directed kinase. In the cyclin D-CDK4-CDKN1B complex, this phosphorylation and consequent CDK4 enzyme activity, is dependent on the tyrosine phosphorylation state of CDKN1B. Thus, in proliferating cells, CDK4 within the complex is phosphorylated on Thr-172 in the T-loop. In resting cells, phosphorylation on Thr-172 is prevented by the non-tyrosine-phosphorylated form of CDKN1B.
• Cellular localizationCytoplasm. Nucleus. Membrane. Cytoplasmic when non-complexed. Forms a cyclin D-CDK4 complex in the cytoplasm as cells progress through G(1) phase. The complex accumulates on the nuclear membrane and enters the nucleus on transition from G(1) to S phase. Also present in nucleoli and heterochromatin lumps. Colocalizes with RB1 after release into the nucleus.

Target information above from: UniProt accession P11802 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 1019 Human
  • Omim: 123829 Human
  • SwissProt: P11802 Human
  • Unigene: 95577 Human

• Alternative names
  Cdk 4 antibodycdk4 antibodyCDK4 protein antibody

  CDK4_HUMAN antibodyCell division kinase 4 antibodyCell division protein kinase 4 antibodyCMM 3 antibodyCMM3 antibodyCrk3 antibodyCyclin dependent kinase 4 antibodyCyclin-dependent kinase 4 antibodyMelanoma cutaneous malignant 3 antibodyMGC14458 antibodyp34 cdk4 antibodyPSK J3 antibodyPSK-J3 antibody

  see all